Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Full-length human dystrophin is a large sarcolemmal protein crucial for maintaining muscle membrane integrity. Mutations in the dystrophin gene cause Duchenne muscular dystrophy (DMD), an X-linked recessive disorder characterized by progressive muscle degeneration. Due to its substantial size (2.4 Mb gene, >11 kb cDNA, 427 kDa protein), delivering the full-length dystrophin gene for therapeutic purposes presents significant challenges for gene therapy. Various approaches, including human artificial chromosomes (HACs), piggyBac transposons, and adeno-associated viral (AAV) vectors, are being explored to enable its expression in muscle cells to ameliorate DMD phenotypes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on full-length human dystrophin.